blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP1648513

EP1648513 - USE OF ADCC-OPTIMIZED ANTIBODIES FOR TREATING PATIENTS ANSWERING WEAKLY TO ANTIBODY TREATMENT [Right-click to bookmark this link]
Former [2006/17]USE OF ADCC-OPTIMIZED ANTIBODIES FOR TREATING WEAK PATIENTS
[2014/29]
StatusPatent revoked
Status updated on  02.10.2021
Database last updated on 20.09.2024
Most recent event   Tooltip08.10.2021Revocation of patentpublished on 10.11.2021  [2021/45]
Applicant(s)For all designated states
Laboratoire Français du Fractionnement et des Biotechnologies
Zone d'Activité de Courtaboeuf
3, avenue des Tropiques
91940 Les Ulis / FR
[2013/34]
Former [2008/19]For all designated states
LFB Biotechnologies
3 Avenue des Tropiques ZA de Courtaboeuf
91940 Les Ulis / FR
Former [2006/17]For all designated states
Laboratoire Français du Fractionnement et des Biotechnologies
Zone d'Activité de Courtaboeuf, 3, avenue des Tropiques
91940 Les Ulis / FR
Inventor(s)01 / BOUREL, Dominique
35, avenue Germaine
F-59110 La Madeleine / FR
02 / JORIEUX, Sylvie
17, rue Molière
F-59650 Villeneuve d'Ascq / FR
03 / DE ROMEUF, Christophe
116, rue de la Bassée
F-59000 Lille / FR
04 / KLEIN, Philippe
6, Rue Corbet
59000- Lille / FR
05 / GAUCHET, Christine
32, Rue des Mésanges
59320- Sédequin / FR
06 / BIHOREAU, Nicolas
36, avenue Parrat
F-91400 Orsay / FR
07 / GAUCHET, Christine
32, Rue des Mésanges
59320 Sequedin / FR
 [2006/17]
Representative(s)Regimbeau
20, rue de Chazelles
75847 Paris Cedex 17 / FR
[2012/49]
Former [2012/30]Faivre Petit, Frédérique, et al
Cabinet Regimbeau 20, rue de Chazelles
75847 Paris Cedex 17 / FR
Former [2006/17]Warcoin, Jacques
Cabinet Régimbeau 20, rue de Chazelles
75847 Paris cedex 17 / FR
Application number, filing date04786018.430.07.2004
[2006/17]
WO2004FR02057
Priority number, dateFR2003000944031.07.2003         Original published format: FR 0309440
[2006/17]
Filing languageFR
Procedural languageFR
PublicationType: A2 Application without search report
No.:WO2005012358
Date:10.02.2005
Language:FR
[2005/06]
Type: A2 Application without search report 
No.:EP1648513
Date:26.04.2006
Language:FR
The application published by WIPO in one of the EPO official languages on 10.02.2005 takes the place of the publication of the European patent application.
[2006/17]
Type: B1 Patent specification 
No.:EP1648513
Date:24.09.2014
Language:FR
[2014/39]
Search report(s)International search report - published on:EP23.03.2006
ClassificationIPC:A61K39/395, A61P37/02, A61P35/00
[2006/17]
CPC:
C07K16/34 (EP,US); A61P1/14 (EP); A61P15/00 (EP);
A61P31/00 (EP); A61P31/06 (EP); A61P31/12 (EP);
A61P33/00 (EP); A61P33/06 (EP); A61P33/12 (EP);
A61P35/00 (EP); A61P35/02 (EP); A61P37/00 (EP);
A61P37/02 (EP); A61P39/02 (EP); A61P43/00 (EP);
A61P7/00 (EP); A61P7/04 (EP); C07K16/18 (US);
C07K16/2833 (EP,US); A61K2039/505 (EP,US); C07K2317/14 (EP,US);
C07K2317/41 (EP,US); C07K2317/732 (EP,US); Y02A50/30 (EP,US) (-)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IT,   LI,   LU,   MC,   NL,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2006/17]
TitleGerman:VERWENDUNG VON ADCC-OPTIMIERTEN ANTIKÖRPERN ZUR BEHANDLUNG VON PATIENTEN, DIE NUR SCHWACH AUF ANTIKÖRPER ANSPRECHEN[2017/29]
English:USE OF ADCC-OPTIMIZED ANTIBODIES FOR TREATING PATIENTS ANSWERING WEAKLY TO ANTIBODY TREATMENT[2017/29]
French:UTILISATION D'ANTICORPS AYANT UNE ADCC OPTIMISÉE POUR TRAITER LES PATIENTS RÉPONDANT FAIBLEMENT AU TRAITEMENT PAR ANTICORPS[2017/29]
Former [2006/17]VERWENDUNG VON ADCC-OPTIMIERTEN ANTIKÖRPERN ZUR BEHANDLUNG VON SCHWACHEN PATIENTEN
Former [2006/17]USE OF ADCC-OPTIMIZED ANTIBODIES FOR TREATING WEAK PATIENTS
Former [2006/17]UTILISATION D'ANTICORPS ANTI-RHESUS DE PRODUITS DANS LA LIGNEE YB2/0
Entry into regional phase30.01.2006National basic fee paid 
30.01.2006Designation fee(s) paid 
30.01.2006Examination fee paid 
Examination procedure30.01.2006Examination requested  [2006/17]
04.08.2008Despatch of a communication from the examining division (Time limit: M06)
28.01.2009Reply to a communication from the examining division
31.07.2009Despatch of a communication from the examining division (Time limit: M06)
01.02.2010Reply to a communication from the examining division
28.06.2011Despatch of a communication from the examining division (Time limit: M06)
19.04.2012Reply to a communication from the examining division
05.10.2012Despatch of a communication from the examining division (Time limit: M04)
08.10.2012Reply to a communication from the examining division
14.02.2013Despatch of a communication from the examining division (Time limit: M04)
07.05.2013Reply to a communication from the examining division
11.04.2014Communication of intention to grant the patent
11.08.2014Fee for grant paid
11.08.2014Fee for publishing/printing paid
11.08.2014Receipt of the translation of the claim(s)
Divisional application(s)EP10181317.8  / EP2275134
EP16203349.2  / EP3159008
The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  04.08.2008
Opposition(s)Opponent(s)01  24.06.2015  10.07.2015  ADMISSIBLE
König Szynka Tilmann von Renesse
Patentanwälte Partnerschaft mbB
Mönchenwerther Strasse 11
40545 Düsseldorf / DE
Opponent's representative
Hemsath, Lars, et al, et al
König-Szynka-Tilmann-von Renesse
Patentanwälte Partnerschaft mbB
Mönchenwerther Straße 11
40545 Düsseldorf / DE
 02  24.06.2015  10.07.2016  ADMISSIBLE
Adams, Harvey Vaughan John
Mathys & Squire LLP The Shard
32 London Bridge Street
London SE1 9SG / GB
Opponent's representative
Wilding, James Roger, et al, et al
Mathys & Squire The Shard
32 London Bridge Street
London SE1 9SG / GB
 [N/P]
Former [2018/22]
Opponent(s)01  24.06.2015  10.07.2015  ADMISSIBLE
König Szynka Tilmann von Renesse
Patentanwälte Partnerschaft mbB
Mönchenwerther Strasse 11
40545 Düsseldorf / DE
Opponent's representative
Hemsath, Lars, et al, et al
König-Szynka-Tilmann-von Renesse
Patentanwälte Partnerschaft mbB
Mönchenwerther Straße 11
40545 Düsseldorf / DE
 02  24.06.2015  10.07.2016  ADMISSIBLE
Adams, Harvey Vaughan John
Mathys & Squire LLP The Shard
32 London Bridge Street
London SE1 9SG / GB
Opponent's representative
Wilding, James Roger, et al, et al
Mathys & Squire LLP The Shard
32 London Bridge Street
London SE1 9SG / GB
Former [2015/47]
Opponent(s)01  24.06.2015  10.07.2015  ADMISSIBLE
König Szynka Tilmann von Renesse
Patentanwälte Partnerschaft mbB
Mönchenwerther Strasse 11
40545 Düsseldorf / DE
Opponent's representative
Hemsath, Lars, et al, et al
König-Szynka-Tilmann-von Renesse
Patentanwälte Partnerschaft mbB
Mönchenwerther Straße 11
40545 Düsseldorf / DE
 02  24.06.2015   
Adams, Harvey Vaughan John
Mathys & Squire LLP The Shard
32 London Bridge Street
London SE1 9SG / GB
Former [2015/31]
Opponent(s)01  24.06.2015   
König Szynka Tilmann von Renesse
Patentanwälte Partnerschaft mbB
Mönchenwerther Strasse 11
40545 Düsseldorf / DE
Opponent's representative
Hemsath, Lars, et al, et al
König-Szynka-Tilmann-von Renesse
Patentanwälte Partnerschaft mbB
Lohengrinstraße 11
40549 Düsseldorf / DE
 02  24.06.2015   
Adams, Harvey Vaughan John
Mathys & Squire LLP The Shard
32 London Bridge Street
London SE1 9SG / GB
31.07.2015Invitation to proprietor to file observations on the notice of opposition
02.02.2016Reply of patent proprietor to notice(s) of opposition
15.05.2017Date of oral proceedings
04.07.2017Despatch of interlocutory decision in opposition
04.07.2017Despatch of minutes of oral proceedings
29.07.2021Legal effect of revocation of patent [2021/45]
24.09.2021Despatch of communication that the patent will be revoked
Appeal following opposition14.09.2017Appeal received No.  T2043/17
14.11.2017Statement of grounds filed
29.07.2021Result of appeal procedure: revocation of the patent
24.09.2021Despatch of the decision of the Board of Appeal
Request for further processing for:The application is deemed to be withdrawn due to failure to reply to the examination report
19.04.2012Request for further processing filed
19.04.2012Full payment received (date of receipt of payment)
Request granted
07.05.2012Decision despatched
Fees paidRenewal fee
30.01.2006Renewal fee patent year 03
11.06.2007Renewal fee patent year 04
26.03.2008Renewal fee patent year 05
13.07.2009Renewal fee patent year 06
14.06.2010Renewal fee patent year 07
20.06.2011Renewal fee patent year 08
18.06.2012Renewal fee patent year 09
17.06.2013Renewal fee patent year 10
11.07.2014Renewal fee patent year 11
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU30.07.2004
BG24.09.2014
CY24.09.2014
CZ24.09.2014
EE24.09.2014
FI24.09.2014
MC24.09.2014
RO24.09.2014
SI24.09.2014
SK24.09.2014
GR25.12.2014
PT26.01.2015
IE30.07.2015
LU30.07.2015
[2017/39]
Former [2016/33]CY24.09.2014
CZ24.09.2014
EE24.09.2014
FI24.09.2014
MC24.09.2014
RO24.09.2014
SI24.09.2014
SK24.09.2014
GR25.12.2014
PT26.01.2015
IE30.07.2015
LU30.07.2015
Former [2016/15]CY24.09.2014
CZ24.09.2014
EE24.09.2014
FI24.09.2014
MC24.09.2014
RO24.09.2014
SI24.09.2014
SK24.09.2014
GR25.12.2014
PT26.01.2015
LU30.07.2015
Former [2016/13]CY24.09.2014
CZ24.09.2014
EE24.09.2014
FI24.09.2014
MC24.09.2014
RO24.09.2014
SI24.09.2014
SK24.09.2014
GR25.12.2014
PT26.01.2015
Former [2016/12]CY24.09.2014
CZ24.09.2014
EE24.09.2014
FI24.09.2014
RO24.09.2014
SI24.09.2014
SK24.09.2014
GR25.12.2014
PT26.01.2015
Former [2015/23]CY24.09.2014
CZ24.09.2014
EE24.09.2014
FI24.09.2014
RO24.09.2014
SK24.09.2014
GR25.12.2014
PT26.01.2015
Former [2015/22]CY24.09.2014
FI24.09.2014
RO24.09.2014
GR25.12.2014
PT26.01.2015
Former [2015/11]CY24.09.2014
FI24.09.2014
GR25.12.2014
Former [2015/09]FI24.09.2014
Cited inInternational search[A]EP0576093  (AETSRN [FR], et al) [A] 1-9,13-15 * page 3, line 11 - line 37 *;
 [X]WO0177181  (LAB FRANCAIS DU FRACTIONNEMENT [FR], et al) [X] 1-9,13-15 * page 35, line 23 - page 37, line 14; claims 1-32 *;
 [DX]  - KUMPEL B M ET AL, "Clearance of red cells by monoclonal IgG3 anti-D in vivo is affected by the VF polymorphism of FcgammaRIIIa (CD16).", CLINICAL AND EXPERIMENTAL IMMUNOLOGY, (200304), vol. 132, no. 1, ISSN 0009-9104, pages 81 - 86, XP001193742 [DX] 1-9,13-15 * the whole document *

DOI:   http://dx.doi.org/10.1046/j.1365-2249.2003.02119.x
 [DA]  - SHINKAWA T ET AL, "The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, (20030131), vol. 278, no. 5, ISSN 0021-9258, pages 3466 - 3473, XP002965857 [DA] 1-9,13-15 * page 3466, column L * * page 3471, column L, paragraph LAST - page 3473, column L, paragraph 1 *

DOI:   http://dx.doi.org/10.1074/jbc.M210665200
 [DA]  - UMANA P ET AL, "ENGINEERED GLYCOFORMS OF AN ANTINEUROBLASTOMA IGG1 WITH OPTIMIZED ANTIBODY-DEPENDENT CELLULAR CYTOTOXIC ACTIVITY", NATURE BIOTECHNOLOGY, NATURE PUBLISHING, US, (199902), vol. 17, ISSN 1087-0156, pages 176 - 180, XP002921620 [DA] 1-9,13-15 * page 176, column L, paragraph 2 - column R, paragraph 2; figure 1 *

DOI:   http://dx.doi.org/10.1038/6179
 [DA]  - SHIELDS R L ET AL, "Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human FcgammaRIII and antibody-dependent cellular toxicity", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, (20020726), vol. 277, no. 30, ISSN 0021-9258, pages 26733 - 26740, XP002964542 [DA] 1-9,13-15 * the whole document *

DOI:   http://dx.doi.org/10.1074/jbc.M202069200
 [DX]  - CARTRON GUILLAUME ET AL, "Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene", BLOOD, & 43RD ANNUAL MEETING OF THE AMERICAN SOCIETY OF HEMATOLOGY, PART 1; ORLANDO, FLORIDA, USA; DECEMBER 07-11, 2001, (20011116), vol. 98, no. 11 Part 1, ISSN 0006-4971, page 602a, XP001193741 [DX] 1-15 * the whole document *

DOI:   http://dx.doi.org/10.1182/blood.V99.3.754
 [X]  - CROWE J S ET AL, "HUMANIZED MONOCLONAL ANTIBODY CAMPATH-1H MYELOMA CELL EXPRESSION OF GENOMIC CONSTRUCTS NUCLEOTIDE SEQUENCE OF CDNA CONSTRUCTS AND COMPARISON OF EFFECTOR MECHANISMS OF MYELOMA AND CHINESE HAMSTER OVARY CELL-DERIVED MATERIAL", CLINICAL AND EXPERIMENTAL IMMUNOLOGY, OXFORD, GB, (1992), vol. 87, no. 1, ISSN 0009-9104, pages 105 - 110, XP008034008 [X] 1,6-10,12-15 * page 106, column L, paragraph 2 * * page 107, column R, line 10 - line 56 *
 [X]  - LIFELY M R (REPRINT) ET AL, "Glycosylation and biological-activity of CAMPATH-1H expressed in different cell-lines and grown under different culture conditions", GLYCOBIOLOGY, IRL PRESS,, GB, (199512), vol. 5, no. 8, ISSN 0959-6658, pages 813 - 822, XP002096118 [X] 1,6-10,12-15 * the whole document *

DOI:   http://dx.doi.org/10.1093/glycob/5.8.813
ExaminationEP1176195
    - N. I. OLOVNIKOVA ET AL, "Effect of Producer Cell Line on Functional Activity of Anti-D Monoclonal Antibodies Destined for Prevention of Rhesus Sensitization", BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE, (20090401), vol. 147, no. 4, doi:10.1007/s10517-009-0516-0, ISSN 0007-4888, pages 448 - 452, XP055000368

DOI:   http://dx.doi.org/10.1007/s10517-009-0516-0
    - SHIELDS R L ET AL, "Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human FcgammaRIII and antibody-dependent cellular toxicity", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, US, (20020726), vol. 277, no. 30, doi:10.1074/JBC.M202069200, ISSN 0021-9258, pages 26733 - 26740, XP002964542

DOI:   http://dx.doi.org/10.1074/jbc.M202069200
    - GUILE G ET AL, "Rapid High-Resolution High-Performance Liquid Chromatographic Method for Separating Glycan Mixtures and Analyzing Oligosaccharide Profiles", ANALYTICAL BIOCHEMISTRY, (1996), vol. 240, pages 210 - 226
    - DWEK R.A ET AL, "Glycobiology: "The function of sugar in the IgG molecule"", J. ANAT., (1995), vol. 187, pages 279 - 292
    - HOLLAND M. ET AL, "Hypogalactosylation of serum IgG in patients with ANCA-associated systemic vasculitis", CLIN EXP IMMUNOL, (2002), vol. 129, pages 183 - 190
    - CHANG K. H. ET AL., "Quantitative analysis of oligosaccharide structure of glycoproteins", BIOTECHNOL. BIOPROCESS ENG., (2000), vol. 5, pages 136 - 140
    - CHARLWOOD J. ET AL, "Characterization of the lycosylation profiles of alzheimer's beta-secretase protein Asp-2 expressed in a variety of cell lines", THE JOURNAL OF BIOLOGICAL CHEMISTRY, (2001), vol. 276, no. 20, pages 16739 - 16748
by applicant   - CARTRON G; DACHEUX L; SALLES G; SOLAL-CELIGNY P; BARDOS P; COLOMBAT P; WATIER H, "Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene", BLOOD, (20020201), vol. 99, no. 3, pages 754 - 8
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.